- July 28, 2025
- March 27, 2025
- January 14, 2025
- October 25, 2024CEOi, together with nearly 100 leading organizations as cosignatories, submitted a letter urging CMS to reconsider preliminary rates for key…
- August 6, 2024
- July 30, 2024
- June 12, 2024Anti-amyloid treatments for early symptomatic Alzheimer disease have recently become clinically available in some countries, which has greatly increased the…
- May 10, 2024The World Health Organization (WHO) put out a call for public consultation on their preferred product characteristics (PPC) blood-based biomarker…
- March 20, 2024The Global CEO Initiative on Alzheimer’s Disease (CEOi) is excited to announce the second phase of its Blood-based Biomarker (BBM)…
- March 19, 2024CEOi held a blood-based biomarker symposium at the American Association for Geriatric Psychiatry (AAGP) 2024 Annual Meeting, “Unleashing Diagnostic Innovation:…